Toggle light / dark theme

From brain implants that allow paralyzed patients to communicate to the wearable devices enhancing our capabilities, brain-computer interfaces could change the way we use our minds forever.

——-
Like this video? Subscribe: https://www.youtube.com/Bloomberg?sub_

Get unlimited access to Bloomberg.com for $1.99/month for the first 3 months: https://www.bloomberg.com/subscriptio

Bloomberg Originals offers bold takes for curious minds on today’s biggest topics. Hosted by experts covering stories you haven’t seen and viewpoints you haven’t heard, you’ll discover cinematic, data-led shows that investigate the intersection of business and culture. Exploring every angle of climate change, technology, finance, sports and beyond, Bloomberg Originals is business as you’ve never seen it.

Subscribe for business news, but not as you’ve known it: exclusive interviews, fascinating profiles, data-driven analysis, and the latest in tech innovation from around the world.

Visit our partner channel Bloomberg Quicktake for global news and insight in an instant.

In a new work, a team from the University of Pennsylvania tracked the impact of alcohol consumption from the age of 20 on brain health and came to disappointing conclusions.


UNIVERSITY PARK, Pa. — Binge drinking in early adults can lead to long-lasting and potentially permanent dysregulation in the brain, according to a new study in mice, led by researchers at Penn State. They found that neurons, cells that transmit information in the brain via electrical and chemical signals, showed changes following binge drinking were similar in many ways to those seen with cognitive decline.

These findings, published in the journal Neurobiology of Aging, reveal that binge drinking early in life may have lasting impacts that are predictive of future health issues, like Alzheimer’s disease and related dementias, the researchers said. The work could inform the development of therapeutics to help combat these changes — particularly in aging populations who may have given up alcohol decades earlier, according to Nikki Crowley, director of the Penn State Neuroscience Institute at University Park, Huck Early Career Chair in Neurobiology and Neural Engineering, assistant professor of biology in the Eberly College of Science, and the leader of the research team.

“We know from previous studies that there are immediate effects of binge drinking on the brain, but we didn’t have any sense of if these changes were long-lasting, or reversible over time,” said Crowley, who is also an assistant professor of biomedical engineering and of pharmacology. “We were interested in understanding if binge drinking during early adulthood may have lasting consequences that are not revealed until later in life — even if drinking had stopped for a very long period of time. This allows us to consider the effects of alcohol on an individual’s holistic health, in terms of their entire life history.”

Summary: Researchers have developed a breakthrough system to deliver large therapeutic molecules into the brain, overcoming the challenges of the blood-brain barrier. The innovative blood-brain barrier-crossing conjugate (BCC) platform utilizes a biological process called γ-secretase-mediated transcytosis to safely transport drugs like oligonucleotides and proteins into the central nervous system via intravenous injection.

In mouse models and human brain tissue, the system effectively silenced harmful genes linked to diseases such as ALS and Alzheimer’s without causing significant side effects. This advancement could revolutionize treatments for neurological and psychiatric disorders, solving a critical challenge in brain research.

Oxford Nanopore Technologies and Wasatch BioLabs have joined forces to develop a groundbreaking direct whole-methylome sequencing (dWMS) product. This collaboration addresses the limitations of traditional methylation sequencing methods, such as bisulfite sequencing and methylation microarrays.

By leveraging Oxford Nanopore’s advanced sequencing technology and Wasatch BioLabs’ proprietary methylation assays, the partners aim to offer a more comprehensive and accurate approach to studying epigenetic modifications. dWMS eliminates the need for harsh chemical treatments and PCR amplification, reducing biases and improving genome-wide coverage.

This innovative technology has the potential to revolutionize epigenetic research, providing valuable insights into the role of methylation in various biological processes and diseases. The collaboration between these two companies is poised to drive significant advancements in genomics and precision medicine.

Watch Dr. Ben Goertzel, CEO of SingularityNET and ASI Alliance, discuss the path to beneficial Superintelligence.

Recorded at the Superintelligence Summit held by Ocean Protocol in Bangkok on November 11, 2024.

SingularityNET was founded by Dr. Ben Goertzel with the mission of creating a decentralized, democratic, inclusive, and beneficial Artificial General Intelligence (AGI). An AGI that is not dependent on any central entity, is open to anyone, and is not restricted to the narrow goals of a single corporation or even a single country.

The SingularityNET team includes seasoned engineers, scientists, researchers, entrepreneurs, and marketers. Our core platform and AI teams are further complemented by specialized teams devoted to application areas such as finance, robotics, biomedical AI, media, arts, and entertainment.

Website: https://singularitynet.io.
X: https://twitter.com/SingularityNET
Instagram: / singularitynet.io.
Discord: / discord.
Forum: https://community.singularitynet.io.
Telegram: https://t.me/singularitynet.
WhatsApp: https://whatsapp.com/channel/0029VaM8
Warpcast: https://warpcast.com/singularitynet.
Mindplex Social: https://social.mindplex.ai/@Singulari
Github: https://github.com/singnet.
Linkedin: / singularitynet.

This capsule…


Inspired by the way that squids use jets to propel themselves through the ocean and shoot ink clouds, researchers from MIT and Novo Nordisk have developed an ingestible capsule that releases a burst of drugs directly into the wall of the stomach or other organs of the digestive tract.

This capsule could offer an alternative way to deliver drugs that normally have to be injected, such as insulin and other large proteins, including antibodies. This needle-free strategy could also be used to deliver RNA, either as a vaccine or a therapeutic molecule to treat diabetes, obesity, and other metabolic disorders.

“One of the longstanding challenges that we’ve been exploring is the development of systems that enable the oral delivery of macromolecules that usually require an injection to be administered. This work represents one of the next major advances in that progression,” says Giovanni Traverso, director of the Laboratory for Translational Engineering and an associate professor of mechanical engineering at MIT, a gastroenterologist at Brigham and Women’s Hospital, an associate member of the Broad Institute, and the senior author of the study.

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get my labs): https://www.ultalabtests.com/partners/michaellustgarten.

Clearly Filtered Water Filter: https://get.aspr.app/SHoPY

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING

NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/

This member-only story is on us. Upgrade to access all of Medium.

Now that AI is transforming nearly every industry, healthcare stands out as a field with immense potential — and unique risks.

A single AI-generated error here could lead to serious consequences for patient health.

Biomedical engineers from the University of Melbourne have invented a 3D printing system, or bioprinter, capable of fabricating structures that closely mimic the diverse tissues in the human body, from soft brain tissue to harder materials like cartilage and bone.

This cutting-edge technology offers cancer researchers an advanced tool for replicating specific organs and tissues, significantly improving the potential to predict and develop new pharmaceutical therapies. This would pave the way for more advanced and ethical drug discovery by reducing the need for animal testing.

Head of the Collins BioMicrosystems Laboratory at the University of Melbourne, Associate Professor David Collins said: In addition to drastically improving print speed, our approach enables a degree of cell positioning within printed tissues. Incorrect cell positioning is a big reason most 3D bioprinters fail to produce structures that accurately represent human tissue.